Inclusion Criteria

INCLUSION CRITERIA:

- Signed Informed Consent.

- Histologically confirmed relapsed or refractory CD20 positive FL grade 1-3a and 1 or
more clearly demarcated lesions with a largest diameter = 1.5 cm, or CD5, CD19, CD20
and CD23 positive relapse or refractory CLL.

- Subjects must have adequate blood, liver, and kidney function.

- Subjects who passed the provided periods from the last anti-cancer treatments at
screening

- ECOG Performance Status of 0-2

- Life expectancy more than 24 weeks at screening

EXCLUSION CRITERIA:

- Current and past malignancy other than FL and CLL within 5 years prior to screening.

- Known Richter's transformation

- Previous autologous stem cell transplantation within 24 weeks prior to screening

- Previous allogeneic stem cell transplantation

- Known CNS involvement

- History of significant cerebrovascular disease

- Current cardiac disease requiring medical treatment

- Chronic or ongoing active infectious disease requiring systemic treatment

- Patients with pleural effusion or ascites detectable by physical examination

- Positive serology test for any of HBsAg, anti-HBc or anti-HCV

- Known HIV positive

- Pregnant or lactating women

- Women of childbearing potential and male patients not willing to use adequate
contraception